272) cellular protein released from bacterial cells is directly proportional to the conc |
273) However, whether the metabolism of immune cells is dysregulated in the TME by cell-i |
274) samples are unavailable or the number of cells is scarce. |
275) Cancer cells treated with C108 or cancer cells wi |
276) ility, and this effect was potentiated in cells treated with CYP1A1 siRNA. |
277) gland dysfunction, primary parotid gland cells treated with PGE2 have increased c-J |
278) nal load is induced in BRCA1-complemented cells treated with a PARPi. |
279) ntitative proteomic study of G1 phase ALL cells treated with vincristine. |
280) 021 that described dysregulated miRNAs in cells or animals infected by SARS-CoV-2 or |
281) reatitis responses in isolated pancreatic cells or lobules. |
282) Mechanistically, treatment of lung cancer cells or lung cancer xenografts with DAC i |
283) otherapy is a treatment that kills cancer cells or stops them from dividing. |
284) analysis of peripheral blood mononuclear cells revealed a significant increase in m |
285) scriptome profiling of hematopoietic stem cells revealed oncogenic and inflammatory |
286) aining of intact and permeabilized HEK293 cells revealed that the N-terminus of 6xHi |
287) expression of 70 SorLA variants in HEK293 cells, revealed that 15 of them (S114R, R3 |
288) ained Ca2+ entry via CRAC pathway in NKT2 cells was apparently mediated by ORAI and |
289) ptake, the viability of gastric carcinoma cells was inhibited more severely than tha |
290) in neonates from ventricular endocardial cells was proposed, we find that late feta |
291) B) from immune infiltrates, ELF3 in tumor cells was upregulated to trigger the activ |
292) implex virus-1 is capable of lysing tumor cells while alerting the immune system. |
293) ystem to directly deliver miRNA to cancer cells while limiting systemic exposure. |
294) ce between effector and regulatory immune cells while preserving the beneficial graf |
295) bited slight or no cytotoxicity on normal cells, while the drug-loaded nanocarrier i |
296) Furthermore, mesenchymal stem cells (MSCs) and cancer-associated fibrobl |
297) or-1 (SDF-1) can recruit mesenchymal stem cells (MSCs) in certain circumstances, whi |
298) We used infant mesenchymal stem cells (MSCs) to experimentally examine cel |
299) ectively blocked glutamine uptake by TNBC cells but not CD8+ T cells, driving synthe |
300) mma (IFN-γ) responses from CD4 and CD8 T cells, but also from natural killer (NK) a |
301) both HBECs and mouse tracheal epithelial cells, but not in CD204 knockout mice. |
302) These compounds label proliferating cells by being incorporated into de novo-s |
303) Analysis of brr6-Y100H cells by electron tomography and Brr6p loc |
304) that ND‑09 induces growth arrest in CML cells by targeting BCR‑ABL. |
|